Albert Lai

List of Publications by Year
in descending order

107 papers	4,629 citations	109321 35 h-index	106344 65 g-index
107 all docs	107 docs citations	107 times ranked	6854 citing authors

#	Article	IF	Citations
1	Characterization of cognitive function in survivors of diffuse gliomas using resting-state functional MRI (rs-fMRI). Brain Imaging and Behavior, 2022, 16, 239-251.	2.1	5
2	Dabrafenib plus trametinib in patients with BRAFV600E-mutant low-grade and high-grade glioma (ROAR): a multicentre, open-label, single-arm, phase 2, basket trial. Lancet Oncology, The, 2022, 23, 53-64.	10.7	165
3	Prognostic value of O6-methylguanine-DNA methyltransferase methylation in isocitrate dehydrogenase mutant gliomas. Neuro-Oncology Advances, 2022, 4, vdac030.	0.7	7
4	Paradoxical Association Between Relative Cerebral Blood Volume Dynamics Following Chemoradiation and Increased Progression-Free Survival in Newly Diagnosed IDH Wild-Type MGMT Promoter Methylated Glioblastoma With Measurable Disease. Frontiers in Oncology, 2022, 12, 849993.	2.8	1
5	Daily functioning in glioma survivors: associations with cognitive function, psychological factorsÂand quality of life. CNS Oncology, 2022, 11, CNS84.	3.0	2
6	Diagnostic and Prognostic Value of pH- and Oxygen-Sensitive Magnetic Resonance Imaging in Glioma: A Retrospective Study. Cancers, 2022, 14, 2520.	3.7	2
7	Characterizing malignant transformation in patients with IDH-mutant glioma.. Journal of Clinical Oncology, 2022, 40, 2065-2065.	1.6	0
8	A single-institution, retrospective examination of new contrast enhancement, progression, and pseudoprogression in IDH mutant glioma.. Journal of Clinical Oncology, 2022, 40, 2043-2043.	1.6	0
9	Voxelwise and Patientwise Correlation of ¹⁸F-FDOPA PET, Relative Cerebral Blood Volume, and Apparent Diffusion Coefficient in Treatment-NaÃ¯ve Diffuse Gliomas with Different Molecular Subtypes. Journal of Nuclear Medicine, 2021, 62, 319-325.	5.0	13
10	Relative oxygen extraction fraction (rOEF) MR imaging reveals higher hypoxia in human epidermal growth factor receptor (EGFR) amplified compared with non-amplified gliomas. Neuroradiology, 2021, 63, 857-868.	2.2	7
11	FoundationOne CDx testing accurately determines whole arm 1p19q codeletion status in gliomas. Neuro-Oncology Advances, 2021, 3, vdab017.	0.7	6
12	Differentiating IDH status in human gliomas using machine learning and multiparametric MR/PET. Cancer Imaging, 2021, 21, 27.	2.8	13
13	Preferential tumor localization in relation to 18F-FDOPA uptake for lowerâ€grade gliomas. Journal of Neuro-Oncology, 2021, 152, 573-582.	2.9	2
14	Worse prognosis for IDH wild-type diffuse gliomas with larger residual biological tumor burden. Annals of Nuclear Medicine, 2021, 35, 1022-1029.	2.2	5
15	Abstract CT025: Dabrafenib plus trametinib in BRAF V600E-mutant high-grade (HGG) and low-grade glioma (LGG). , 2021, , .		5
16	Human IDH mutant 1p/19q co-deleted gliomas have low tumor acidity as evidenced by molecular MRI and PET: a retrospective study. Scientific Reports, 2020, 10, 11922.	3.3	23
17	Multiparametric MR-PET measurements in hypermetabolic regions reflect differences in molecular status and tumor grade in treatment-naÃ¯ve diffuse gliomas. Journal of Neuro-Oncology, 2020, 149, 337-346.	2.9	5
18	Decorin expression is associated with predictive diffusion MR phenotypes of anti-VEGF efficacy in glioblastoma. Scientific Reports, 2020, 10, 14819.	3.3	13

#	Article	IF	Citations
19	Diffusion Magnetic Resonance Imaging Phenotypes Predict Overall Survival Benefit From Bevacizumab or Surgery in Recurrent Glioblastoma With Large Tumor Burden. Neurosurgery, 2020, 87, 931-938.	1.1	14
20	Diffusion MRI changes in the anterior subventricular zone following chemoradiation in glioblastoma with posterior ventricular involvement. Journal of Neuro-Oncology, 2020, 147, 643-652.	2.9	5
21	Rate of change in maximum 18F-FDOPA PET uptake and non-enhancing tumor volume predict malignant transformation and overall survival in low-grade gliomas. Journal of Neuro-Oncology, 2020, 147, 135-145.	2.9	12
22	Glioblastoma Utilizes Fatty Acids and Ketone Bodies for Growth Allowing Progression during Ketogenic Diet Therapy. IScience, 2020, 23, 101453.	4.1	47
23	Patterns of long-term survivorship following bevacizumab treatment for recurrent glioma: a case series. CNS Oncology, 2019, 8, CNS35.	3.0	7
24	Mechanisms of Resistance to EGFR Inhibition Reveal Metabolic Vulnerabilities in Human GBM. Molecular Cancer Therapeutics, 2019, 18, 1565-1576.	4.1	11
25	Association between Tumor Acidity and Hypervascularity in Human Gliomas Using pH-Weighted Amine Chemical Exchange Saturation Transfer Echo-Planar Imaging and Dynamic Susceptibility Contrast Perfusion MRI at 3T. American Journal of Neuroradiology, 2019, 40, 979-986.	2.4	24
26	Design and Evaluation of an External Control Arm Using Prior Clinical Trials and Real-World Data. Clinical Cancer Research, 2019, 25, 4993-5001.	7.0	57
27	Metabolic characterization of human IDH mutant and wild type gliomas using simultaneous pH- and oxygen-sensitive molecular MRI. Neuro-Oncology, 2019, 21, 1184-1196.	1.2	28
28	SPINT2 is hypermethylated in both IDH1 mutated and wild-type glioblastomas, and exerts tumor suppression via reduction of c-Met activation. Journal of Neuro-Oncology, 2019, 142, 423-434.	2.9	8
29	Validation of vessel size imaging (VSI) in high-grade human gliomas using magnetic resonance imaging, image-guided biopsies, and quantitative immunohistochemistry. Scientific Reports, 2019, 9, 2846.	3.3	32
30	pH-weighted amine chemical exchange saturation transfer echoplanar imaging (CEST-EPI) as a potential early biomarker for bevacizumab failure in recurrent glioblastoma. Journal of Neuro-Oncology, 2019, 142, 587-595.	2.9	28
31	NIMG-54. DIFFUSION MRI PHENOTYPES PREDICT OVERALL SURVIVAL BENEFIT FROM BEVACIZUMAB IN RECURRENT GLIOBLASTOMA WITH A LARGE TUMOR BURDEN: EVIDENCE FROM CLINICAL PRACTICE AND A MULTICENTER PHASE 3 TRIAL. Neuro-Oncology, 2019, 21, vi173-vi173.	1.2	0
32	CBMT-31. HDAC INHIBITION DIMINISHES THE GROWTH OF ENDOGENOUS IDH MUTANT GLIOMAS. Neuro-Oncology, 2019, 21, vi39-vi40.	1.2	2
33	QOLP-12. EVALUATION OF THE UCLA NEURO-ONCOLOGY PROGRAM PSYCHOSOCIAL PATIENT SCREENING FORM IN IDENTIFYING DEPRESSION, FATIGUE, AND PERCEIVED COGNITIVE FUNCTION IN PATIENTS WITH GLIOMAS. Neuro-Oncology, 2019, 21, vi200-vi200.	1.2	0
34	NIMG-60. IDH MUTANT GLIOMAS WITH 1p/19q CO-DELETION ARE LESS ACIDIC THAN NON-CO-DELETED GLIOMAS AS MEASURED WITH PH-WEIGHTED AMINE CEST-MRI AND AMINO ACID PET. Neuro-Oncology, 2019, 21, vi174-vi175.	1.2	0
35	ACTR-30. UPDATED EFFICACY AND SAFETY OF DABRAFENIB PLUS TRAMETINIB IN PATIENTS WITH RECURRENT/REFRACTORY BRAF V600Eâ€“MUTATED HIGH-GRADE GLIOMA (HGG) AND LOW-GRADE GLIOMA (LGG). Neuro-Oncology, 2019, 21, vi19-vi20.	1.2	20
36	GENE-38. IDH1MUT INDUCES N6-METHYLADENOSINE (m6A) RNA HYPERMETHYLATION VIA D-2-HG IN GLIOMA. Neuro-Oncology, 2019, 21, vi105-vi106.	1.2	0

#	Article	IF	Citations
37	NIMG-31. BRAIN CONNECTIVITY PATTERNS CHARACTERIZE COGNITIVE IMPAIRMENT IN LONG-TERM SURVIVORS OF LOW-GRADE GLIOMA (LGG) USING RESTING-STATE FUNCTIONAL MRI (rs-fMRI). Neuro-Oncology, 2019, 21, vi167-vi168.	1.2	0
38	NCOG-10. RELATIONSHIP BETWEEN COGNITIVE FUNCTION, MOOD, AND FUNCTIONING IN GLIOMA SURVIVORS. Neuro-Oncology, 2019, 21, vi160-vi161.	1.2	0
39	Bevacizumab at first recurrence after standard radio-chemotherapy is associated with improved overall survival in glioblastoma patients with large tumor burden. Neuro-Oncology Practice, 2019, 6, 103-111.	1.6	3
40	18F-FDOPA PET and MRI characteristics correlate with degree of malignancy and predict survival in treatment-naÃ¯ve gliomas: a cross-sectional study. Journal of Neuro-Oncology, 2018, 139, 399-409.	2.9	32
41	Simultaneous p<scp>H</scp>â€sensitive and oxygenâ€sensitive <scp>MRI</scp> of human gliomas at 3 <scp>T</scp> using multiâ€echo amine proton chemical exchange saturation transfer spinâ€andâ€gradient echo echoâ€planar imaging (<scp>CESTâ€SAGEâ€EPI</scp>). Magnetic Resonance in Medicine, 2018, 80, 1962-1978.	3.0	38
42	Phase 2 Study of Bortezomib Combined With Temozolomide and Regional Radiation Therapy for Upfront Treatment of Patients With Newly Diagnosed Glioblastoma Multiforme: Safety and Efficacy Assessment. International Journal of Radiation Oncology Biology Physics, 2018, 100, 1195-1203.	0.8	45
43	D-2-Hydroxyglutarate Is Necessary and Sufficient for Isocitrate Dehydrogenase 1 Mutantâ€“Induced MIR148A Promoter Methylation. Molecular Cancer Research, 2018, 16, 947-960.	3.4	8
44	Tissue microarray analysis for epithelial membrane protein-2 as a novel biomarker for gliomas. Brain Tumor Pathology, 2018, 35, 1-9.	1.7	12
45	RARE-09. EFFICACY AND SAFETY OF DABRAFENIB + TRAMETINIB IN PATIENTS WITH RECURRENT/REFRACTORY BRAF V600Eâ€“MUTATED HIGH-GRADE GLIOMA (HGG). Neuro-Oncology, 2018, 20, vi238-vi238.	1.2	3
46	NIMG-15. DIFFERENTIATION OF IDH1 MUTANT AND WILD TYPE GLIOMAS USING pH- AND OXYGEN-SENSITIVE MOLECULAR MRI. Neuro-Oncology, 2018, 20, vi178-vi179.	1.2	0
47	NIMG-59. VALIDATION OF QUANTITATIVE VESSEL SIZE IMAGING (VSI) IN HUMAN GLIOMAS USING IMAGE-GUIDED STEREOTACTIC BIOPSIES. Neuro-Oncology, 2018, 20, vi189-vi189.	1.2	0
48	ACTR-10. A RANDOMIZED, PHASE I/II TRIAL OF IXAZOMIB IN COMBINATION WITH STANDARD THERAPY FOR UPFRONT TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED MGMT METHYLATED GLIOBLASTOMA (GBM) STUDY DESIGN. Neuro-Oncology, 2018, 20, vi13-vi13.	1.2	0
49	Mono-exponential, diffusion kurtosis and stretched exponential diffusion MR imaging response to chemoradiation in newly diagnosed glioblastoma. Journal of Neuro-Oncology, 2018, 139, 651-659.	2.9	25
50	Durable complete responses in some recurrent high-grade glioma patients treated with Toca 511 + Toca FC. Neuro-Oncology, 2018, 20, 1383-1392.	1.2	135
51	Metabolic characterization of isocitrate dehydrogenase (IDH) mutant and IDH wildtype gliomaspheres uncovers cell type-specific vulnerabilities. Cancer & Metabolism, 2018, 6, 4.	5.0	55
52	A gene expression signature predicts recurrence-free survival in meningioma. Oncotarget, 2018, 9, 16087-16098.	1.8	26
53	HumanTERTpromoter mutation enables survival advantage fromMGMTpromoter methylation inIDH1wild-type primary glioblastoma treated by standard chemoradiotherapy. Neuro-Oncology, 2017, 19, now189.	1.2	65
54	Incidence, survival, pathology, and genetics of adult Latino Americans with glioblastoma. Journal of Neuro-Oncology, 2017, 132, 351-358.	2.9	34

#	Article	IF	Citations
55	Perfusion and diffusion MRI signatures in histologic and genetic subtypes of WHO grade IIâ€“III diffuse gliomas. Journal of Neuro-Oncology, 2017, 134, 177-188.	2.9	118
56	Early experience with formalin-fixed paraffin-embedded (FFPE) based commercial clinical genomic profiling of gliomas-robust and informative with caveats. Experimental and Molecular Pathology, 2017, 103, 87-93.	2.1	7
57	Report of safety of pulse dosing of lapatinib with temozolomide and radiation therapy for newly-diagnosed glioblastoma in a pilot phase II study. Journal of Neuro-Oncology, 2017, 134, 357-362.	2.9	22
58	Baseline pretreatment contrast enhancing tumor volume including central necrosis is a prognostic factor in recurrent glioblastoma: evidence from single and multicenter trials. Neuro-Oncology, 2017, 19, 89-98.	1.2	68
59	NCMP-01. SEIZURE CONTROL AFTER INITIAL PRESENTATION IN IDH MUTATED GLIOMA PATIENTS. Neuro-Oncology, 2017, 19, vi135-vi136.	1.2	1
60	GENE-41. EPIGENETIC DOWN-REGULATION OF THE METALLOTHIONEIN FAMILY IN ISOCITRATE DEHYDROGENASE (IDH) MUTANT GLIOMAS. Neuro-Oncology, 2017, 19, vi101-vi101.	1.2	0
61	DDIS-10. TARGETING HGF/MET IN GBM BY RESTORING SPINT2 FUNCTION. Neuro-Oncology, 2016, 18, vi49-vi49.	1.2	0
62	NIMG-31. RESIDUAL ENHANCING TUMOR VOLUME IS AÂSTRONG PROGNOSTIC BIOMARKER FOR SURVIVAL IN BOTH NEWLY DIAGNOSED AND RECURRENT GBM REGARDLESS OF THERAPY: EVIDENCE FROM 1,535 PATIENTS IN SINGLE AND MULTICENTER TRIALS. Neuro-Oncology, 2016, 18, vi131-vi131.	1.2	0
63	NIMG-56. PATTERNS FROM DYNAMIC VESSEL SIZE IMAGING OF ARTERIAL AND VENOUS PERFUSION CORRELATES WITH AGGRESSIVENESS AND STRATIFIES 1p19q CO-DELETED FROM NON-CODELETED LOW-GRADE GLIOMAS. Neuro-Oncology, 2016, 18, vi136-vi137.	1.2	0
64	Large-scale assessment of the gliomasphere model system. Neuro-Oncology, 2016, 18, 1367-1378.	1.2	82
65	Simulation, phantom validation, and clinical evaluation of fast pHâ€weighted molecular imaging using amine chemical exchange saturation transfer echo planar imaging (CESTâ€EPI) in glioma at 3â€‰T. NMR in Biomedicine, 2016, 29, 1563-1576.	2.8	51
66	Phase 1 trial of vocimagene amiretrorepvec and 5-fluorocytosine for recurrent high-grade glioma. Science Translational Medicine, 2016, 8, 341ra75.	12.4	158
67	Contrastâ€enhancing tumor growth dynamics of preoperative, treatmentâ€naive human glioblastoma. Cancer, 2016, 122, 1718-1727.	4.1	47
68	Bidirectional Contrast agent leakage correction of dynamic susceptibility contrast (DSC)â€MRI improves cerebral blood volume estimation and survival prediction in recurrent glioblastoma treated with bevacizumab. Journal of Magnetic Resonance Imaging, 2016, 44, 1229-1237.	3.4	27
69	Association between lesion location and language function in adult glioma using voxel-based lesion-symptom mapping. NeuroImage: Clinical, 2015, 9, 617-624.	2.7	23
70	Bone morphogenetic protein 7 sensitizes O6-methylguanine methyltransferase expressing-glioblastoma stem cells to clinically relevant dose of temozolomide. Molecular Cancer, 2015, 14, 189.	19.2	38
71	Ribosomal Proteins RPS11 and RPS20, Two Stress-Response Markers of Glioblastoma Stem Cells, Are Novel Predictors of Poor Prognosis in Glioblastoma Patients. PLoS ONE, 2015, 10, e0141334.	2.5	52
72	TheMGMTpromoter SNP rs16906252 is a risk factor forMGMTmethylation in glioblastoma and is predictive of response to temozolomide. Neuro-Oncology, 2015, 17, 1589-1598.	1.2	57

#	Article	IF	Citations
73	2-Hydroxyglutarate Inhibits ATP Synthase and mTOR Signaling. Cell Metabolism, 2015, 22, 508-515.	16.2	190
74	Relationship Between [18F]FDOPA PET Uptake, Apparent Diffusion Coefficient (ADC), and Proliferation Rate in Recurrent Malignant Gliomas. Molecular Imaging and Biology, 2015, 17, 434-442.	2.6	28
75	Quantification of Nonenhancing Tumor Burden in Gliomas Using Effective T2 Maps Derived from Dual-Echo Turbo Spin-Echo MRI. Clinical Cancer Research, 2015, 21, 4373-4383.	7.0	27
76	pH-weighted molecular imaging of gliomas using amine chemical exchange saturation transfer MRI. Neuro-Oncology, 2015, 17, 1514-1524.	1.2	96
77	Radial expansion rates and tumor growth kinetics predict malignant transformation in contrast-enhancing low-grade diffuse astrocytoma. CNS Oncology, 2015, 4, 247-256.	3.0	16
78	Diffusion MRI Characteristics after Concurrent Radiochemotherapy Predicts Progression-Free and Overall Survival in Newly Diagnosed Glioblastoma. Tomography, 2015, 1, 37-43.	1.8	12
79	Patient-Specific Metrics of Invasiveness Reveal Significant Prognostic Benefit of Resection in a Predictable Subset of Gliomas. PLoS ONE, 2014, 9, e99057.	2.5	89
80	Increased sensitivity to radiochemotherapy in IDH1 mutant glioblastoma as demonstrated by serial quantitative MR volumetry. Neuro-Oncology, 2014, 16, 414-420.	1.2	82
81	Deferred use of bevacizumab for recurrent glioblastoma is not associated with diminished efficacy. Neuro-Oncology, 2014, 16, 1427-1428.	1.2	6
82	BI-10 * pH-WEIGHTED MRI IN HUMAN GLIOMAS. Neuro-Oncology, 2014, 16, v25-v25.	1.2	0
83	Recurrent Glioblastoma Treated with Bevacizumab: Contrast-enhanced T1-weighted Subtraction Maps Improve Tumor Delineation and Aid Prediction of Survival in a Multicenter Clinical Trial. Radiology, 2014, 271, 200-210.	7.3	150
84	Deferred use of bevacizumab for recurrent glioblastoma is not associated with diminished efficacy. Neuro-Oncology, 2014, 16, 815-822.	1.2	49
85	Tumor-Suppressive miR148a Is Silenced by CpG Island Hypermethylation in IDH1-Mutant Gliomas. Clinical Cancer Research, 2014, 20, 5808-5822.	7.0	30
86	PET Parametric Response Mapping for Clinical Monitoring and Treatment Response Evaluation in Brain Tumors. PET Clinics, 2013, 8, 201-217.	3.0	8
87	Overexpression of isocitrate dehydrogenase mutant proteins renders glioma cells more sensitive to radiation. Neuro-Oncology, 2013, 15, 57-68.	1.2	128
88	Lyophilized brain tumor specimens can be used for histologic, nucleic acid, and protein analyses after 1 year of room temperature storage. Journal of Neuro-Oncology, 2013, 113, 365-373.	2.9	23
89	Combined analysis of O6-methylguanine-DNA methyltransferase protein expression and promoter methylation provides optimized prognostication of glioblastoma outcome. Neuro-Oncology, 2013, 15, 370-381.	1.2	97
90	Identifying the mesenchymal molecular subtype of glioblastoma using quantitative volumetric analysis of anatomic magnetic resonance images. Neuro-Oncology, 2013, 15, 626-634.	1.2	91

#	Article	IF	Citations
91	Contrast-enhanced T1-weighted subtraction maps for response assessment in recurrent glioblastoma treated with bevacizumab.. Journal of Clinical Oncology, 2013, 31, 2055-2055.	1.6	4
92	Final results of a single-arm phase II study of bevacizumab and temozolomide following radiochemotherapy in newly dignosed adult glioblastoma patients.. Journal of Clinical Oncology, 2013, 31, 2076-2076.	1.6	1
93	Patient-specific biomathematical model to predict benefit of resection in human gliomas.. Journal of Clinical Oncology, 2013, 31, e13017-e13017.	1.6	0
94	18F-FDOPA and 18F-FLT positron emission tomography parametric response maps predict response in recurrent malignant gliomas treated with bevacizumab. Neuro-Oncology, 2012, 14, 1079-1089.	1.2	99
95	Bevacizumab as first-line therapy for glioblastoma. Future Oncology, 2012, 8, 929-938.	2.4	7
96	Identification of Retinol Binding Protein 1 Promoter Hypermethylation in Isocitrate Dehydrogenase 1 and 2 Mutant Gliomas. Journal of the National Cancer Institute, 2012, 104, 1458-1469.	6.3	56
97	Anatomic localization of O6-methylguanine DNA methyltransferase (MGMT) promoter methylated and unmethylated tumors: A radiographic study in 358 de novo human glioblastomas. NeuroImage, 2012, 59, 908-916.	4.2	128
98	Rosette-forming glioneuronal tumor: a pineal region case with IDH1 and IDH2 mutation analyses and literature review of 43 cases. Journal of Neuro-Oncology, 2011, 102, 477-484.	2.9	68
99	Evidence for Sequenced Molecular Evolution of IDH1 Mutant Glioblastoma From a Distinct Cell of Origin. Journal of Clinical Oncology, 2011, 29, 4482-4490.	1.6	420
100	Phase II Study of Bevacizumab Plus Temozolomide During and After Radiation Therapy for Patients With Newly Diagnosed Glioblastoma Multiforme. Journal of Clinical Oncology, 2011, 29, 142-148.	1.6	418
101	The L84F polymorphic variant of human O6-methylguanine-DNA methyltransferase alters stability in U87MG glioma cells but not temozolomide sensitivity. Neuro-Oncology, 2009, 11, 22-32.	1.2	12
102	Tyrosineâ€dependent basolateral targeting of human connexin43â€“eYFP in Madinâ€“Darby canine kidney cells can be disrupted by the oculodentodigital dysplasia mutation L90V. FEBS Journal, 2009, 276, 6992-7005.	4.7	5
103	Phase II Pilot Study of Bevacizumab in Combination with Temozolomide and Regional Radiation Therapy for Up-Front Treatment of Patients With Newly Diagnosed Glioblastoma Multiforme: Interim Analysis of Safety and Tolerability. International Journal of Radiation Oncology Biology Physics, 2008, 71, 1372-1380.	0.8	169
104	Safety of anticoagulation use and bevacizumab in patients with glioma. Neuro-Oncology, 2008, 10, 355-360.	1.2	85
105	Relationship between Survival and Edema in Malignant Gliomas: Role of Vascular Endothelial Growth Factor and Neuronal Pentraxin 2. Clinical Cancer Research, 2007, 13, 2592-2598.	7.0	108
106	Oculodentodigital dysplasia connexin43 mutations result in non-functional connexin hemichannels and gap junctions in C6 glioma cells. Journal of Cell Science, 2006, 119, 532-541.	2.0	91
107	Signal-dependent Trafficking of Î²-Amyloid Precursor Protein-Transferrin Receptor Chimeras in Madin-Darby Canine Kidney Cells. Journal of Biological Chemistry, 1998, 273, 3732-3739.	3.4	35